Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

at 06:50 Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow Gilead Sciences, Inc. today presented ... Fennec Pharmaceuticals Inc. , a commercial ...

Gilead is committed to designing trials to help understand how HIV treatment and prevention impact populations that have been ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences' magrolimab ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights ...

Y-o-Y Growth and Strong Performance in 2024 The Small Molecule API market is anticipated to exhibit a Y-o-Y growth of 4.6% in ...